Core Insights - The Ministry of Agriculture and Rural Affairs has officially approved the "Duck Viral Hepatitis Bivalent Yolk Antibody (Type 1 + Type 3)" developed by Harbin Pharmaceutical Group's subsidiary, marking a significant achievement in veterinary medicine [1] - The product addresses critical issues in the aquaculture industry, specifically targeting the severe threats posed by Type 1 and Type 3 duck hepatitis viruses [2] - The successful technology transfer indicates strong market recognition of the product, highlighting a shift from a technology-driven approach to a value-driven model for Harbin Pharmaceutical Group [3][4] Group 1: Product Development and Approval - The new veterinary drug is a specific biological agent developed independently by Harbin Vaccine, effectively preventing Type 1 and Type 3 duck hepatitis viruses [2] - The antibody efficacy remains stable at a high level of 1:280, providing reliable immune protection for ducklings [2] Group 2: Market Potential and Competitive Advantage - The product demonstrates significant market potential, with rapid efficacy within 16 hours and a low adverse reaction rate of less than 0.1% [3] - The successful technology transfer reflects market validation and establishes a positive cycle of project initiation, research, evaluation, transformation, and revenue generation for the company [3] Group 3: Future Outlook - The dual success of approval and technology transfer is a testament to the company's research capabilities and its model of "independent research and development for value creation" [4] - Harbin Vaccine aims to continue addressing real industry challenges and enhancing market value through increased research investment [4]